Objective: The Protein Production, Monoclonal Antibody, Tissue Culture Shared Resource (PPSR) supports basic and translational research at UCCC with validated cell lines, preparation of hybridomas, production of monoclonal antibodies, isolation and titering of baculovirus expressing recombinant proteins, and large scale preparation of recombinant proteins and monoclonal antibodies. Services &Technologies: PPSR provides assays pertinent to cancer research, including generation of hybridomas with desired properties to novel antigens, production of monoclonal antibodies, production of recombinant baculovirus that express proteins of interest, large scale cultivation of cells of varying types, and validated tumor cell lines known to be free of contaminants. In FY2010, 74 human tumor cell lines have been validated for use by UCC investigators. The facility has biosafety cabinets, tissue culture incubators, an ELISA plate reader, bioreactors including three GE Wave bioreactors for large scale cultivation of cells, refrigerators, freezers, and liquid nitrogen storage systems for maintaining stocks of cell lines. Consultation &Training: PPSR provides consultation and technical support to help members prepare and isolate hybridomas that produce monoclonal antibodies with the desired properties directed against their proteins of interest. The facility also provides consultation and technical support for preparation, isolation, and production of recombinant baculovirus vectors encoding proteins of interest to support biochemical, molecular, and structural studies by UCCC members, including large volume (0.5 to 10 I) cultures of insect cells producing the protein of interest. Validated tumor cell lines are maintained by the PPSR allowing UCCC investigators to utilize cell lines known to reflect the original tumor cell line, and to be free of contaminating species, in their research. Utilization: PPSR has served 48 UCCC members from all 6 Programs and 3 consortium institutions. The majority of the reagents and cell lines provided by the PPSR support multiple basic and translational projects. Management and Finances: This resource is UCCC-managed. 61% of the operating budget comes from charge backs to UCCC users who represent 76% of the total users. PPSR requests ~$300K CCSG support for 48% of its operating budget. This increase represents the continuation of the cell line validation service currently supported by ARRA funding. Increased funding will continue our ability to meet the needs of the cancer research community to generate and utilize recombinant proteins, monoclonal antibodies, and provide the community with validated tumor cell lines free of contaminants for use in basic and translational research programs.

Public Health Relevance

The Protein Production / Monoclonal Antibody / Tissue Culture Shared Resource provides a centralized services to make cancer-related proteins for UCCC members to study their mechanism of action in identified drugs and cancer-related biomarkers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-26
Application #
8616657
Study Section
Subcommittee G - Education (NCI)
Project Start
2014-02-05
Project End
2017-01-31
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
26
Fiscal Year
2014
Total Cost
$136,832
Indirect Cost
$47,643
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Pei, Shanshan; Minhajuddin, Mohammad; Adane, Biniam et al. (2018) AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell 23:86-100.e6
Ren, Shengxiang; Rivard, Christopher J; Yu, Hui et al. (2018) A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clin Lung Cancer 19:450-456
Donson, Andrew M; Amani, Vladimir; Warner, Elliot A et al. (2018) Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol Cancer Ther 17:1984-1994
Branchford, B R; Stalker, T J; Law, L et al. (2018) The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost 16:352-363
Wahdan-Alaswad, R S; Edgerton, S M; Salem, H S et al. (2018) Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer. J Oncol Transl Res 4:
Ryan, Weston Kenneth; Fernandez, Josiah; Peterson, Mikayla Katherine et al. (2018) Activation of S6 signaling is associated with cell survival and multinucleation in hyperplastic skin after epidermal loss of AURORA-A Kinase. Cell Death Differ :
Monks, Jenifer; Orlicky, David J; Stefanski, Adrianne L et al. (2018) Maternal obesity during lactation may protect offspring from high fat diet-induced metabolic dysfunction. Nutr Diabetes 8:18
Garcia, Tamara B; Fosmire, Susan P; Porter, Christopher C (2018) Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine. Leuk Res 64:30-33
Helfrich, Barbara A; Gao, Dexiang; Bunn Jr, Paul A (2018) Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy. Lung Cancer 118:148-154
Oweida, Ayman; Phan, Andy; Vancourt, Benjamin et al. (2018) Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. Thyroid 28:739-747

Showing the most recent 10 out of 1634 publications